Brief: Sirnaomics Doses The First Patient In Phase I Clinical Trial Of RNAi Therapeutic STP705 In Adults Undergoing Abdominoplasty For Medical Aesthetics Treatment
07/11/2022 23:08
Nov 7 (Reuters) - Sirnaomics Ltd 2257.HK :
* SIRNAOMICS DOSES THE FIRST PATIENT IN PHASE I CLINICAL
TRIAL OF
RNAI THERAPEUTIC STP705 IN ADULTS UNDERGOING ABDOMINOPLASTY FOR
MEDICAL AESTHETICS TREATMENT
Source text for Eikon: ID:nPn7PfMNCa
Further company coverage: 2257.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million